Skip to content

Pretreatment radiomic biomarker for immunotherapy responder and prognosis prediction in advanced NSCLC patients

Pretreatment radiomic biomarker for immunotherapy responder and prognosis prediction in advanced NSCLC patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075551
Enrollment
Unknown
Registered
2023-09-08
Start date
2020-12-28
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Gold Standard:Durable clinical benefit based on RECIST1.1 criteria

Sponsors

Guangdong Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age greater than 18 years old (2) Thin layer enhanced CT of the lungs with measurable lesions (length diameter = 10mm) (3) Without immunotherapy and radiation therapy in the lung area before CT examination (4) Non small cell lung cancer confirmed by biopsy pathology (5) Complete 1mm thin-layer enhanced CT (6) Reconstruction of images through standard algorithms (7) Complete clinical data;

Exclusion criteria

Exclusion criteria: i. Previous history of other tumors Ii Received radiation therapy in the lung area before receiving immunotherapy Iii. Types of difficult to delineate lesions such as malignant pleural effusion Iv. Pathological confirmation contains other components except for small cell lung cancer

Design outcomes

Primary

MeasureTime frame
Durable clinical benefit;

Countries

China

Contacts

Public ContactZhou Haiyu

Guangdong Provincial People's Hospital

zhouhaiyu@gdph.org.cn+86 137 1034 2002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026